Local heterogeneity in Lassa fever serology in rural Nigeria: Implications for vaccine trial site selection Authors: David Simons, Christina Harden, Natalie Imirzian, Katharine E. T. Thompson, Nzube Michael Ifebueme, Sunday Eziechina, Helen Ignatius, Diana Marcus, Fisayomi Aderibigbe, James T. Koninga, Martin Meremikwu, Lina Moses, David W. Redding, Sagan Friant, David Safronetz, David Safronetz, David Safronetz, David Safronetz Published: 2026 ABSTRACT IntroductionLassa virus (LASV) causes significant morbidity in West Africa, yet vaccine trial planning is hampered by a lack of high-resolution, community-level seroprevalence data. We aimed to characterize the fine-scale spatial and demographic heterogeneity of LASV exposure in rural Nigeria to inform site selection strategies.MethodsWe conducted a cross-sectional serosurvey across nine villages in three Nigerian states (Benue, Ebonyi, and Cross River). We recruited 1,874 individuals and tested for LASV IgG using the highly specific Panadea LASV IgG ELISA. We employed Bayesian hierarchical models to estimate seroprevalence and investigated 21 pre-specified demographic, environmental, and behavioral risk factors for association with seropositivity. Village-specific transmission dynamics were explored using Bayesian generalized additive models for age-stratified seroprevalence.ResultsThe overall model-based IgG seroprevalence was 3.2% (95% CrI: 2.5–4.0%). We observed marked fine-scale heterogeneity, with village-level estimates ranging from 0.8% to 6.5%. Age-seroprevalence curves suggested? divergent transmission dynamics, ranging from cumulative endemic exposure to recent focal outbreaks in younger cohorts. Likely constrained by low overall prevalence and high exposure ubiquity, univariable analyses detected no strong or consistent associations between seropositivity and the 21 pre-specified risk factors, including rodent consumption and agricultural practices. No significant village-wide spatial clustering of seropositive households was observed via Local Getis-Ord (Gi*).DiscussionLASV exposure in rural Nigeria is characterized by low overall prevalence punctuated by significant hyper-local variation. The lack of consistent individual-level risk factors and the divergent age-exposure profiles suggest that risk may be influenced by stochastic, localized ecological drivers or obscured by the temporal misalignment of cross-sectional surveys. Vaccine trial site selection must move beyond regional incidence data to incorporate interdisciplinary, One Health metrics including high-resolution human serosurveillance and longitudinal reservoir monitoring to identify active transmission hotspots. Introduction Lassa virus (Mammarenavirus lassaense; Arenaviridae, LASV) is a zoonotic arenavirus endemic to West Africa, with regular outbreaks occurring in Nigeria, Guinea, Liberia, and Sierra Leone. It causes Lassa fever, a viral hemorrhagic illness responsible for an estimated 900,000 annual infections and over 200 deaths annually in Nigeria alone [1]. Clinical presentation ranges from asymptomatic infection to severe hemorrhagic fever with case fatality exceeding 20% in hospitalized patients, for whom treatment options remain limited [2]. The primary reservoir for LASV is Mastomys natalensis, a highly fecund, synanthropic rodent widely distributed across sub-Saharan Africa [3]. It thrives in agricultural and peri-domestic environments, creating substantial opportunities for human contact [4]. Infected rodents, particularly those infected vertically in utero, can become persistent shedders of the virus in excreta, while its fluctuating population dynamics influence seasonal transmission intensity [5,6]. Human infection occurs primarily through direct or indirect contact with infected rodents, their excreta, contaminated food, or aerosolized particles [7]. Occupational and domestic exposures, particularly in farming, food storage, and rodent hunting contexts, are commonly implicated. However, the relative contribution of these pathways remains debated, and seroprevalence surveys show that exposure is widespread yet highly variable, with most infections (~80%) being asymptomatic or subclinical, meaning case counts severely underestimate the true infection burden [8,9]. Environmental and ecological conditions strongly influence LASV spillover [10]. Land use changes like deforestation and agricultural intensification can increase human-rodent contact, while shifts in rodent community composition may also moderate risk [11–13]. Despite these broad-scale drivers, observed variation in LASV prevalence between ecologically similar areas highlights the critical importance of fine-scale factors [14]. These include social conditions, such as household structure, food storage methods, and specific human-animal interactions. Understanding this fine-scale variation is not solely academic but is a prerequisite for the successful deployment of future medical countermeasures LASV is a designated priority pathogen for the World Health Organization and the Coalition for Epidemic Preparedness Innovations (CEPI), with multiple vaccine candidates currently advancing into clinical trials [15]. The success of future Phase III efficacy trials relies on identifying communities where incidence is sufficient to measure a vaccine effect. However, relying on broad-scale incidence data or passive surveillance to select these sites risks recruitment failure if transmission is more focal than regional risk maps suggest, resulting in prolonged timelines for case accrual sufficient to demonstrate vaccine efficacy [16]. Current Lassa fever surveillance relies primarily on passive case detection at sentinel hospitals, which overlooks mild infections and asymptomatic seroconversion in the community [17]. As a result, major gaps remain in our understanding of the null areas and regions that appear ecologically suitable but report few cases. To address this, we conducted a cross-sectional study in nine communities across three Nigerian states [18]. We combined serological testing with structured questionnaires to investigate fine-scale drivers of exposure. Our objectives were to: 1) estimate LASV seroprevalence at state and village levels; 2) characterize individual and household correlates of seropositivity; and 3) explore spatial heterogeneity in local transmission risk. Materials and methods The primary objective of this study was to estimate the seroprevalence of LASV IgG in nine communities across three Nigerian states. Secondary objectives were to explore demographic, environmental, behavioral, and occupational correlates of seropositivity and to assess fine-scale spatial heterogeneity of exposure. Ethics statement The study protocol was approved by the Institutional Review Board of the Pennsylvania State University, USA (STUDY00019989), and by the Nigerian National Health Research Ethics Committee (AEC/03/168/24). Additional approval was obtained from the health research ethics committees of the public health agencies in each participating state. The study was conducted in accordance with the Declaration of Helsinki. Enrolment involved engagement with community leaders. Written informed consent was obtained from all adults; assent and written parental consent were obtained for minors. Study design and participants This cross-sectional baseline survey was conducted as part of the SCAPES longitudinal study [18]. Nine villages across three states (Benue [BN], Ebonyi [EB], and Cross River [CR]) were selected using a systematic framework designed to sample communities across a gradient of postulated drivers of LASV spillover [19]. These states were chosen to represent a range of environmental suitability as defined by national-scale mechanistic modelling, which categorized them into high, medium, and low-risk tiers [20]. Using the site selection tool [19], candidate settlements were identified via OpenStreetMap. Land cover characteristics (ESA WorldCover) were analyzed within a 2-km radius representing the home range of the reservoir species (M. natalensis) to ensure sites reflected rural agricultural areas. We specifically targeted medium-sized villages (100–500 households) and excluded sites with >60% forest cover or >20% built-up area. Final site selection was validated to ensure no systematic bias relative to other settlements in the region and to ensure the sampled villages appropriately reflected the local variation in cropland and grassland proportions. This approach was designed to represent a spectrum of LASV spillover risk across the three states, rather than targeting known hotspot communities, thereby providing a more representative baseline of regional seroprevalence. To contextualize our findings within the national epidemiological landscape, we collated historical passive surveillance data from the Nigeria Centre for Disease Control (NCDC) [21]. Specifically, we extracted the number of years each corresponding Local Government Area (LGA) had reported confirmed Lassa fever cases prior to the survey [22]. Households were enumerated to estimate population size and plan recruitment. Villages ranged from 110 to 321 households (population 465–2,313; S1 Fig). To prevent demographic sampling bias (such as over-representing individuals who remain at home during the day), we employed a strict intra-household quota system. We aimed to recruit ~20% of households per village (target ~70), specifically enrolling exactly four individuals per household: one adult male, one adult female, one adolescent (12–18), and one randomly selected child (<12). This approach was designed to ensure the final cohort accurately reflected the balanced demographic structure of the communities. Children under 12 provided dried blood spot (DBS) samples but did not complete questionnaires. Based on published LASV seroprevalence data [14,17,23], we assumed high-risk (>40% seroprevalence), medium-risk (10–20%), and low-risk (<5%) village categories. We estimated that 180 individuals would provide 80% power (α = 0.05, β = 0.2) to detect significant differences in LASV seroprevalence between village categories. Household-level clustering of serostatus was expected; hence, the design was powered to detect differences at both village and household levels. Systematic sampling was used to select households within each village. Routes were designed to approach every nth household (where n is the total number of households divided by the target sample size). Three households (all in BN) declined participation; in these instances, the next household was enrolled. The participant flow diagram is available in S2 Fig. Data collection A questionnaire covering demographic, environmental, behavioral, and occupational domains was administered [24]. DBS samples were collected by finger-prick on Whatman 903 cards, air-dried, and transported with desiccant. DBS was selected as the primary sampling modality due to the logistical challenges of maintaining a continuous cold-chain for serum during extended sampling sessions (typically two weeks per village) in remote rural locations. Samples were eluted and tested for LASV IgG using the Panadea LASV ELISA kit following the manufacturer’s protocol modified for DBS [25,26]. Specifically, two 6mm discs were extracted from the DBS samples of an individual and were eluted in a 300 µL solution of 1 × PBS containing 0.2% liquid ammonium and 2.5 µL of a 25% NH3 solution following previously validated protocols for LASV antibody recovery. Samples were incubated overnight at 4°C, and the resulting eluates were used directly for ELISA without further dilution. This recombinant nucleoprotein (NP)-based assay was selected for its high specificity compared to traditional whole-virus lysate assays, which are prone to cross-reactivity with other endemic arenaviruses. In analytical validation studies, this platform has demonstrated a diagnostic specificity of 100% and a sensitivity of 95% against reference cohorts [26]. Consistent with its use for identifying baseline exposure, the assay threshold was set according to the manufacturer’s instructions for qualitative detection of IgG. Statistical methods Analyses were performed in R (v4.2.3) utilizing the tidyverse package (v2) [27,28]. Visualizations were produced using the ggplot2 package (v4.0.01) and the gtsummary package (v2.4.0) for tables [29, 30]. Questionnaire responses were linked to individual and household records using unique identifiers. Household GPS coordinates were used for spatial analyses. Data cleaning involved range validation, logical consistency checks, and outlier flagging. Missingness was negligible (<1%); analyses were restricted to complete cases. Descriptive group comparisons To compare characteristics between villages or states, we fitted separate Bayesian hierarchical models using the brms (v2.22.0) and RStan (v2.32.7) packages, specifically Gaussian linear models for continuous variables and multinomial logistic regression for categorical data [31,32]. Following the principles of Bayesian hierarchical modelling, we assessed group-level heterogeneity by examining the posterior distribution of the standard deviation (SD) of the random effect [33]. Unlike frequentist p-values or Odds Ratios (where the null is 1.0), the SD represents the magnitude of among-group variance on the link scale. We defined “strong evidence” of a notable difference when the 95% CrI of the SD was entirely displaced from zero, with a lower bound >0.1; this ensured the identified variation was of a meaningful magnitude rather than a statistical artefact of the regularizing prior [33]. Estimating LASV seroprevalence We estimated seroprevalence and 95% CrIs using Bayesian generalized linear mixed models (GLMM) with a binary outcome (seropositive/seronegative) and a single fixed effect for state or village. Posterior predictions generated marginal estimates averaged over sampled individuals. To explore age-related variation, we fitted a Bayesian generalized additive model (GAM) with village-specific smooth terms for age. Posterior expected probabilities were calculated across a grid of age values to obtain modelled estimates. The full posterior summaries (central estimates and CrIs) for these models are presented in S2 and S3 Tables. Differences classed as important are indicated in the main text and tables. We utilized weakly informative priors for all fixed effects (Normal(0, 5)) and random effects (Exponential(1)) to allow the data to drive inference while stabilizing computation in low-prevalence groups. We did not attempt to formally estimate the Force of Infection (FOI) using catalytic models. Such models typically assume a time-invariant infection hazard, which we deemed inappropriate given the evidence of stochastic, episodic transmission in this region. Furthermore, the low number of seropositive cases (N = 61) across a wide age range precluded the stable estimation of a time-varying FOI model, which would require substantially higher power to distinguish between age-dependent risk and historical fluctuations in viral circulation. Characterizing behavioral and exposure correlates of seropositivity We investigated associations between LASV seropositivity and a range of a priori risk factors using a Bayesian GLMM framework, specifying a Bernoulli (logit) likelihood for serostatus as the binary outcome. Analyses were conducted at both individual and household levels, with explanatory variables grouped into four conceptual domains: demographic, environmental, behavioral, and occupational (S1 Table). To account for potential non-independence of observations within villages, reflecting shared environmental, infrastructural, or cultural exposures, a random intercept for village was included in all models. Univariable models were fitted separately for each covariate to examine associations in isolation, adjusting only for village-level clustering. We evaluated the magnitude and uncertainty of potential risk factors by examining the posterior odds ratios (OR) and their 95% CrIs. An interval that included 1.0 was interpreted as showing no strong evidence for an association. Unlike the descriptive comparisons above, which used the random effect SD to identify village-level heterogeneity, these models report the fixed-effect OR to quantify the specific relationship between a covariate and the probability of seropositivity. Exploring spatial heterogeneity in LASV exposure To assess spatial patterns in LASV exposure at the household level, we geocoded each sampled household and identified those with at least one seropositive individual. We used the terra (v1.8-60) and tidyterra (v1) packages to process spatial data [34,35]. We first applied Global Moran’s I to test for overall spatial autocorrelation of household seropositivity within each village. To identify potential micro-scale clustering, we then used local Getis-Ord Gi* analysis using the spdep package (v1.3-13), which compares the value at each household (the proportion of seropositive members) to the values of neighboring households within a defined spatial lag (300m), generating a z-score indicating statistically significant hot spots (high-value clusters) and cold spots (low-value clusters) [36]. As a post hoc check on the relationship between hotspot classification and seropositivity, we fit a simplified logistic regression model. This model used household serostatus (presence/absence of seropositive individuals) as the outcome and compared two groups: households located in any Gi* defined cluster (Hotspot or Coldspot) versus those classified as Not Significant. This allowed us to robustly quantify the association between being in a statistically-defined cluster and the household’s observed seropositivity. Given the low seroprevalence and relatively small village area (median = 6.7km2), these analyses were intended as descriptive and exploratory, with a focus on identifying potential micro-scale heterogeneity rather than formally testing for clustering. Results Study population Between 16 December 2023 and 22 July 2024, we enrolled 1,926 individuals (1,874 obtained DBS samples, 1,469 completed questionnaires) from 577 households across nine villages in three Nigerian states (BN, CR, EB). This sample represented 27% of households and 11% of the expected total village population (Table 1, Table 2 and S1 Fig). 10.1371/journal.pntd.0014379.t001Table 1Household-level demographic and environmental characteristics.Benue [BN]Cross River [CR]Ebonyi [EB]CharacteristicNOverall N = 5771Zugu N = 631Dyegh N = 641Ikyogbakpev N = 641Okimbongha N = 641Ogamanna N = 661Ofonekom N = 611Ezeakataka N = 661Enyandulogu N = 651Offianka N = 641 Number of households 2 205 (31%)305 (21%)149 (43%)191 (34%)231 (29%)110 (55%)321 (21%)281 (23%)381 (17%) Household size (individuals) 3 5776.0 (4.0)6.0 (4.0)8.0 (3.3)7.0 (4.0)6.0 (3.3)6.0 (3.8)4.0 (3.0)6.0 (3.8)6.0 (5.0)6.0 (3.0) Household seropositivity 4 555All negative496 (89%)58 (97%)58 (91%)58 (91%)43 (73%)53 (80%)42 (89%)64 (97%)61 (94%)59 (92%)At least one positive59 (11%)2 (3.3%)6 (9.4%)6 (9.4%)16 (27%)13 (20%)5 (11%)2 (3.0%)4 (6.2%)5 (7.8%) Number of buildings 3 5773.0 (2.0)4.0 (3.0)3.5 (2.0)4.0 (3.0)2.0 (0.0)2.0 (0.0)2.0 (0.0)3.0 (1.0)3.0 (2.0)3.0 (2.0) Single-room buildings 3 5771.0 (2.0)4.0 (3.0)3.0 (2.0)4.0 (3.0)1.0 (1.0)1.0 (1.0)1.0 (0.0)1.0 (1.0)2.0 (1.0)1.0 (1.0) Proximity to bush 3 577293 (51%)52 (83%)32 (50%)48 (75%)14 (22%)25 (38%)8 (13%)42 (64%)49 (75%)23 (36%) Proximity to farm 3 577382 (66%)59 (94%)49 (77%)58 (91%)12 (19%)14 (21%)10 (16%)59 (89%)58 (89%)63 (98%) Type of toilet 3 577 Plumbed toilet325 (4.3%)8 (13%)6 (9.4%)4 (6.3%)3 (4.7%)2 (3.0%)0 (0%)0 (0%)2 (3.1%)0 (0%) Pit latrine377 (13%)16 (25%)13 (20%)12 (19%)5 (7.8%)3 (4.5%)0 (0%)8 (12%)4 (6.2%)16 (25%) Open system313 (2.3%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)1 (1.6%)8 (12%)3 (4.6%)1 (1.6%) Field defecation3460 (80%)37 (59%)45 (70%)48 (75%)56 (88%)61 (92%)60 (98%)50 (76%)56 (86%)47 (73%) Other32 (0.3%)2 (3.2%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%) Rodents enter home 577540 (94%)62 (98%)62 (97%)59 (92%)61 (95%)62 (94%)56 (92%)56 (85%)62 (95%)60 (94%)1 Median (IQR); n (%)2 % refers to proportion of households enrolled from all households in the village3 Indicates strong evidence of heterogeneity between villages for this variable. Posterior summaries quantifying these between-village differences are detailed in S4 Table4 Maximum of 4 household members were tested irrespective of household size Household-level demographic and environmental characteristics. 1 Median (IQR); n (%) 2 % refers to proportion of households enrolled from all households in the village 3 Indicates strong evidence of heterogeneity between villages for this variable. Posterior summaries quantifying these between-village differences are detailed in S4 Table 4 Maximum of 4 household members were tested irrespective of household size 10.1371/journal.pntd.0014379.t002Table 2Individual-level demographic, occupational, and behavioral characteristics.Benue [BN]Cross River [CR]Ebonyi [EB]CharacteristicNOverall N = 1,8411Zugu N = 1791Dyegh N = 2091Ikyogbakpev N = 2081Okimbongha N = 2251Ogamanna N = 2301Ofonekom N = 1431Ezeakataka N = 2341Enyandulogu N = 2081Offianka N = 2051 Estimated village population 1,227 (15%)930 (23%)2,242 (9%)1,196 (21%)1,401 (16%)464 (40%)2,125 (11%)1,790 (12%)2,310 (9%) LASV Seropositive 1,84161 (3.3%)2 (1.1%)6 (2.9%)8 (3.8%)16 (7.1%)13 (5.7%)5 (3.5%)2 (0.9%)4 (1.9%)5 (2.4%) Age (years) 1,84127 (32)30 (27)27 (31)27 (31)26 (28)25 (29)26 (25)28 (30)30 (34)26 (32) Sex: Female 1,841948 (51%)83 (46%)104 (50%)95 (46%)121 (54%)114 (50%)75 (52%)127 (54%)113 (54%)116 (57%) Education 2 1,402 None224 (16%)16 (12%)36 (23%)27 (17%)35 (21%)9 (5.1%)15 (13%)24 (14%)28 (18%)34 (22%) Primary535 (38%)53 (38%)51 (32%)51 (32%)42 (25%)61 (34%)25 (22%)110 (63%)80 (52%)62 (41%) Secondary581 (41%)64 (46%)64 (41%)81 (51%)80 (47%)97 (55%)67 (58%)41 (23%)43 (28%)44 (29%) Post-secondary62 (4.4%)6 (4.3%)6 (3.8%)1 (0.6%)13 (7.6%)10 (5.6%)9 (7.8%)1 (0.6%)4 (2.6%)12 (7.9%) Born in study village 2 1,3981,031 (74%)80 (58%)83 (53%)96 (61%)149 (88%)169 (95%)101 (87%)132 (75%)111 (72%)110 (72%) Occupation: Farmer 1,8411,083 (59%)129 (72%)132 (63%)121 (58%)123 (55%)145 (63%)101 (71%)117 (50%)104 (50%)111 (54%) Occupation: Agricultural worker 1,841151 (8.2%)8 (4.5%)9 (4.3%)9 (4.3%)13 (5.8%)21 (9.1%)3 (2.1%)31 (13%)32 (15%)25 (12%) Occupation: Trader 1,841312 (17%)39 (22%)46 (22%)28 (13%)25 (11%)20 (8.7%)15 (10%)53 (23%)40 (19%)46 (22%) Rodent consumption 2 1,404777 (55%)127 (91%)144 (91%)144 (90%)113 (66%)130 (73%)72 (62%)14 (8.0%)7 (4.5%)26 (17%) Past rodent consumption only 2 627446 (71%)10 (83%)11 (79%)13 (81%)32 (56%)30 (63%)30 (68%)109 (67%)113 (76%)98 (78%) Ever rodent consumption 2 1,4041,223 (87%)137 (99%)155 (98%)157 (98%)145 (85%)160 (90%)102 (88%)123 (70%)120 (77%)124 (82%) Cleaned rodent excreta 1,4071,231 (87%)95 (67%)143 (91%)130 (81%)157 (92%)167 (94%)110 (95%)155 (88%)133 (86%)141 (93%)1 n (%); Median (IQR)2 Indicates strong evidence of heterogeneity between villages for this variable. Posterior summaries quantifying these between-village differences are detailed in S4 Table Individual-level demographic, occupational, and behavioral characteristics. 1 n (%); Median (IQR) 2 Indicates strong evidence of heterogeneity between villages for this variable. Posterior summaries quantifying these between-village differences are detailed in S4 Table Households Household composition and infrastructure showed notable variation across the study villages, particularly in household structure (Table 1). There was strong evidence of differences in household size, ranging from median sizes of 8 in Dyegh [BN] to 4 in Ofonekom [CR]. Similarly, the number of buildings per household and number of single-room buildings differed substantially between villages, with households in BN generally being larger and comprising more buildings. Environmental characteristics were more consistent across sites. Proximity to bush (51%) and farms (66%), predominant sanitation method (field defecation: 80%), and rodent entry into homes (94%) did not show strong evidence of differing between villages. Households employed various methods for rodent removal. In contrast to the uniformity of rodent entry, our analysis found strong evidence that the specific methods used, such as poison (73%), sticks (44%), and traps, varied substantially between villages. However, the ultimate outcome for captured rodents was largely consistent; 88% of households reported disposing of them. While disposal was uniform, the practice of consuming captured rodents did show notable variation between villages, consistent with the individual-level data (Table 2). Individuals Demographics and behaviors varied notably across sites (Table 2). Migration patterns differed (Strong Evidence); the percentage of residents born in their current village was substantially lower in BN compared to CR. However, most participants were permanent residents (median 12 months/year). A balanced distribution by sex was achieved by the sampling design for all sites. Median age (Overall: 28, IQR: 31) was consistent across villages. Educational attainment varied substantially; participants in BN and CR had higher rates of secondary education completion compared to EB. Subsistence farming was the most common occupation (59%), followed by trading (17%) and hired agricultural work (6%). Primary occupations did not show strong evidence of difference between villages. Rodent consumption practices differed substantially. Current rodent consumption was common in most BN and CR villages (e.g., 91% in Dyegh [BN] and 73% in Ogamanna [CR]) but was rarer in the EB villages (e.g., 4.5% in Enyandulogu). Even among those not currently consuming rodents, the proportion who reported past consumption also varied, being generally higher in EB villages (e.g., 78% in Offianka) than elsewhere. Indirect rodent contact, such as cleaning rodent excreta, was nearly universal (99%) and did not differ between villages. LASV seroprevalence estimates Of the 1,874 individuals tested, 61 were seropositive for LASV IgG, yielding a crude overall seroprevalence of 3.3%. These individuals belonged to 59 households, with only two households (both in Ikyogbakpev [BN]) containing more than one seropositive member. No seropositive individuals reported a prior diagnosis of Lassa fever. Model-based estimates revealed marked heterogeneity in exposure risk across the study area (Table 3). The overall seroprevalence was 3.17% (95% CrI: 2.47-4.04%). This varied at the state level (CR = 5.13% [3.66–6.97%]; BN = 2.63% [1.56–4.06%]; EB = 1.65% [0.86–2.85%]) and showed even greater variation at the village level (ranging from Ezeakataka [EB] = 0.79% [0.13-2.45%] to Okimbongha [CR] = 6.48% [3.9-9.97%]) (Table 3.). 10.1371/journal.pntd.0014379.t003Table 3Model-based LASV IgG seroprevalence estimates at the state and village level.Seropositive95% CrIState/VillageNn%LowerUpper Benue 616162.631.564.06Dyegh21662.741.085.47Ikyogbakpev21483.721.706.82Zugu18621.030.173.28 Cross River 597345.133.666.97Ofonekom14052.670.965.73Ogamanna234135.533.068.94Okimbongha223166.483.909.97 Ebonyi 661111.650.862.85Enyandulogu21541.810.554.23Ezeakataka23920.790.132.45Offianka20752.310.834.88 Model-based LASV IgG seroprevalence estimates at the state and village level. When contextualized against historical national surveillance records, the sampled villages fell within three distinct Local Government Areas representing a gradient of historical case reporting: Izzi LGA in Ebonyi (cases reported in 7 historical years, most recently 2024), Ikom LGA in Cross River (2 years, most recently 2022), and Vande Ikya LGA in Benue (1 year, most recently 2022). Notably, marked heterogeneity in village-level seroprevalence was observed even among communities nested within the same historically active LGA, highlighting a disconnect between aggregate regional notifications and true community-level exposure. The relationship between age and seropositivity was not uniform, revealing distinct, village-specific transmission dynamics (Fig 1). Two villages (Ogamanna [CR] and Ofonekom [CR]) exhibited the classic pattern of increasing seroprevalence with age, consistent with long-term, cumulative exposure. This trend was highly consistent in Ogamanna [CR] (Posterior probability of increase > 99%), while Ofonekom [CR] showed a similar but more uncertain trajectory (Probability ~76%). Notably, these two villages are geographically adjacent (< 5km apart), suggesting a more similar local ecology. Conversely, Okimbongha [CR] and Ezeakataka [EB] displayed profiles peaking in younger groups before declining, which may suggest more recent, focal exposure, or the preferential waning of older antibodies, though statistical evidence for the decline was weaker (Probability 60–66%). In remaining villages, seroprevalence remained consistently low across ages. Village-specific age-seroprevalence curves for Lassa virus. Colored lines represent median posterior estimates from a Bayesian generalized additive model, and shaded ribbons show the 95% credible intervals. Villages are grouped by state (columns). Within each panel, background grey lines display the median estimates for the other two surveyed villages within the same state to provide local comparative context. Note that the y-axis scales vary between states to accommodate the marked regional differences in estimated seroprevalence. Risk factors for seropositivity Univariable models adjusting for village-level clustering found no strong evidence of association between seropositivity and most pre-specified risk factors (Fig 2). Odds ratios were generally close to 1.0 with wide intervals. Given these results and the study’s power limitations from overall low seropositivity, multivariable modelling was deemed unnecessary, we therefore only report univariable results below. Forest plot of univariable associations with Lassa virus seropositivity. Points represent median posterior odds ratios derived from Bayesian hierarchical logistic regression models, with horizontal bars denoting 95% credible intervals. All models include a village-level random effect to account for spatial clustering. Variables are grouped by epidemiological domain. For continuous predictors (e.g., age, household size, number of buildings), the odds ratio reflects the change in odds per single-unit increase; for categorical predictors, the odds ratio reflects the comparison against a defined baseline reference group. Demographic correlates of LASV seropositivity No meaningful association was found for age (OR: 1.01 [0.99–1.02]) or sex (OR: 1.06 [0.64–1.76]). Post-secondary education showed a protective trend (OR: 0.39 [0.17–0.90]), though likely confounded by age and socioeconomic status. Environmental and Behavioral correlates of LASV seropositivity No clear associations were found for household-level variables such as household size (OR: 0.97, [0.89–1.06]), number of buildings (OR: 0.80, [0.62–1.00]), rodent entry into the home (OR: 0.72, [0.27–2.30]), or cleaning of rodent excreta (OR: 0.42 [0.06–9.64]). Odds ratios for rodent consumption (OR: 0.93 [0.49–1.80]) and past rodent consumption only (OR: 0.59 [0.23–1.46]), and ever consuming rodents (OR: 0.67 [0.33-1.53]) were also uncertain. Univariable analysis for all selected variables are shown in S1 Table. Spatial heterogeneity in LASV exposure We assessed the spatial clustering of LASV seropositivity at the household level across nine villages. Global spatial autocorrelation, assessed using Moran’s I, found no evidence of significant village-wide clustering in any site (all p > 0.05). Localized clustering was then evaluated using the Getis-Ord Gi* statistic, which identified a total of 27 hotspot and 6 coldspot households across all villages (Fig 3). However, these statistical clusters did not align well with observed seropositivity; of the 59 seropositive households in the study, only 3.6% were located within a designated hotspot. Spatial distribution of household LASV seropositivity and Local Gi* clustering. Each panel represents a single village, showing jittered household locations. Shapes indicate whether at least one LASV-seropositive individual was recorded in the household. The color classification reflects the local clustering of seropositivity, where the Gi* test includes the household’s own value in the local average; a high-value central household may thus be classified as ‘Not significant’ if surrounding seronegative households dilute its local average below the statistical threshold. Scale bars are included to indicate spatial scale; coordinates are not shown to preserve privacy. Logistic regression confirmed no significant difference in the odds of seropositivity based on cluster status (p = 0.39 OR clustered vs. non-clustered = 0.53 [0.12-2.3]). These results strongly indicate that, in our study sites, seropositive households were not concentrated in discernible spatial clusters. Discussion This study found that LASV exposure in rural Nigeria was substantially lower than anticipated based on national risk models [10]. While the overall model-based IgG seroprevalence was 3.2% (2.5–4.0%), this aggregate figure masks marked heterogeneity at the local scale. Prevalence varied significantly between states (1.7% to 5.1%) and between villages (0.8% to 6.5%). These findings challenge broad-scale risk mapping, pointing to a transmission landscape that is generally low but punctuated by complex, hyper-local variation supported by three observations: divergent age patterns, an absence of risk factor correlation, and a lack of spatial clustering. While the degree of local variation reported here is notable, such fine-scale spatial heterogeneity is a well-documented feature of zoonoses, where transmission is highly dependent on micro-scale ecological interfaces [37]. Our seroprevalence estimates are comparable to those from some contemporary community-based studies in West Africa, though such comparisons are conditioned by differences in study populations and laboratory methods [14,38]. In Sierra Leone, seroprevalence was found to range between 0% and 88% at the village level across three districts, while in two Nigerian local government areas (Abuja Municipal Area Council and Ikorodu), seroprevalence was 33% and 18% respectively [14,39]. The high specificity of the commercial ELISA kit (LASV vs. non-LASV arenaviruses) used in this study may yield more conservative estimates than alternative serological assays, particularly given the known circulation of non-Lassa arenaviruses in Nigeria [26,40]. The relationship with age was more revealing. Two villages exhibited classic increasing seroprevalence with age, indicative of cumulative, endemic transmission. Conversely, two others showed peaks in younger groups, which may suggest dynamic, focal transmission [41]. Peaks in younger age groups could arise from recent increases in transmission or immunological factors like seroreversion. With antibody waning estimated at ~3% annually [42], the decline in older cohorts likely reflects the loss of detectable markers from historical infections. This implies that cross-sectional seroprevalence may serve only as a moving window of recent exposure (e.g., the last 15–20 years) rather than a cumulative record of lifetime risk. Consequently, the distinct peak in younger age groups observed in villages like Okimbongha [CR] could signal more recent transmission events concentrated in younger cohorts, while the low prevalence in older adults reflects a mixture of lower recent exposure and the decay of historical antibodies. From a trial planning perspective, these communities with steep age-seroprevalence gradients in younger cohorts likely represent the most viable candidates for efficacy studies, as they may indicate active, ongoing viral circulation rather than solely historical exposure. While our univariable models did not identify age as a significant population-wide correlate of seropositivity (OR: 1.01 [0.99–1.02]), the village-specific GAMs reveal that age-related risk is not uniform across the study area. This suggests that age does not act as a consistent biological or behavioral risk factor in isolation, but rather acts as a proxy for the varying duration and timing of exposure events at the community level. Consistent with this theme of local heterogeneity, our univariable analyses revealed no strong or consistent demographic, environmental, or occupational correlates of seropositivity. The lack of clear associations with commonly cited risks, such as farming or rodent consumption (despite reported consumption up to 91% in BN and CR), contrasts with some previous findings and suggests that transmission may occur more frequently through indirect routes, such as food contamination [43]. However, the absence of associations may be a function of the study’s limited statistical power to detect modest individual-level effects, given the low overall seroprevalence (N = 61) and limited evidence for prior effect sizes to guide adequate a priori powering. Furthermore, the near-universal reporting of certain exposures, such as the presence of rodents in homes (94%), creates little variability for comparison, mathematically obscuring potential effects. We must also acknowledge alternative explanations, specifically that self-reported behaviors are subject to recall bias and measurement error, and cross-sectional questionnaires may temporally misalign current habits with historical exposure events. Collectively, these findings suggest that if human behavior cannot be reliably used to predict risk in this setting, exposure is likely influenced by the primary missing component of the risk pathway: the local density and viral shedding status of the rodent reservoir [4,11]. Our findings highlight a vulnerability in the planning of Phase III vaccine efficacy trials. We found that being located within a high-risk state or Local Government Area does not guarantee high local exposure. We found that being located within a high-risk state or a historically highly-notified Local Government Area (such as Izzi LGA, which has reported confirmed cases in 7 different years) does not guarantee high, uniform local exposure across its constituent communities. Consequently, trial sites selected based on regional notification rates may inadvertently target villages with insufficient transmission intensity to demonstrate vaccine efficacy. To mitigate this risk, clinical trial site selection must adopt a One Health trial design framework [16]. Operationally, this shifts trial planning from a reactive reliance on lagging human clinical indicators to a predictive model driven by leading ecological and socio-behavioral data. A One Health approach integrates proactive ecological surveillance of the reservoir (e.g., tracking M. natalensis population dynamics and epizootic cycles), viral genomics, and continuous socio-behavioral monitoring to capture fluctuations in the human-animal interface. Strengths and limitations The strengths of this study include its systematic, multi-criteria site selection; a large sample size across diverse communities; and a robust analytical framework using Bayesian mixed models to account for data hierarchies and uncertainty. The inclusion of formal spatial statistics adds rigor to our conclusion that transmission is not strongly clustered at the household level; however, we note that our ability to detect micro-clustering is inherently constrained by the low overall prevalence, the specific spatial scale of the analysis, and our quota sampling design, which captured only a subset of individuals per household. Nevertheless, the study has important limitations. It was powered to detect village-level differences based on higher seroprevalence estimates from previous studies; however, the observed low seroprevalence limited our power for individual-level risk factor analysis. While our analysis was causally structured using a priori directed acyclic graphs [18], the cross-sectional design fundamentally limits precise temporal resolution and the distinction between recent and past infections. Consequently, while baseline seroprevalence is a superior screening tool compared to regional risk maps, it remains a proxy for true incidence. Ideally, serosurveys should be used to stratify villages for subsequent prospective incidence studies. This challenge is compounded by the potential for antibody waning and sero-reversion, the rates of which are vital for accurate FOI estimation but remain poorly understood for LASV. Additionally, the measurement of behavior and environment at a single cross-sectional point may not accurately reflect cumulative lifetime exposure, as housing and habits vary over time. Reliance on self-reported behaviors is subject to recall bias, and the study lacked objective ecological measures, such as rodent abundance data. A further limitation is the potential for reduced diagnostic sensitivity associated with the use of DBS eluates. While DBS offers significant logistical advantages, elution from filter paper has been shown to result in a 4.6-fold reduction in the mean ELISA index value compared to matched whole-blood samples [26]. In head-to-head comparisons, this resulted in a lower proportion of positive detections (15% for DBS vs 29% for whole blood). Consequently, our reported seroprevalence of 3.3% should be viewed as a conservative estimate that may under-represent individuals with low antibody titers, potentially associated with more historical exposures. However, the high specificity of the ELISA (100% in reference cohorts) and high agreement with other platforms like Indirect Fluorescent Antibody (IFA) tests (93.1% overall agreement; 𝜅 = 0.81) ensures that the identified spatial hotspots and village-level differences are robust [26]. This high specificity is particularly important for vaccine trial site selection, where the risk of false-positive results from cross-reactive arenaviruses must be minimised. Finally, the reduced sensitivity of DBS eluates has specific implications for the interpretation of age-stratified seroprevalence. If historical, low-titer antibodies are more likely to fall below the limit of detection, our findings may be subject to a recency bias. This could artificially exaggerate the appearance of peaks in younger cohorts while masking cumulative exposure in older individuals. When coupled with the estimated annual seroreversion rate of 3% [42], this technical limitation reinforces the view that our results represent a moving window of recent exposure rather than a complete record of lifetime risk. Consequently, while the divergent age patterns we observed strongly suggest local heterogeneity in transmission history, the absolute magnitude of cumulative exposure in older adults is likely under-represented. Public health implications and future directions The absence of spatial clustering and a clear risk profile suggests that geographically-targeted human interventions may be inefficient. Instead, public health efforts should prioritize broadly-deployed, household-level interventions (e.g., rodent-proofing) and maintain high suspicion in surveillance across all villages within endemic regions, not just sentinel sites. Surveillance must also include areas of previously low-predicted risk given the observed micro-heterogeneity. Our findings highlight a vulnerability in Phase III vaccine efficacy trials: being located within a high-risk state or LGA does not guarantee high local exposure. Trial sites selected based on regional notification rates may inadvertently target villages with insufficient transmission intensity to demonstrate efficacy. To mitigate this risk, clinical trial site selection must adopt the One Health trial design framework discussed above. By moving beyond passive surveillance data to incorporate granular, active human serosurveys alongside prospective, longitudinal monitoring of rodent reservoirs, researchers can ensure trials are enrolled in locations where the virus is demonstrably circulating in the animal host. This integrated strategy maximizes the likelihood of capturing spillover events and identifying active transmission hotspots. Future research must leverage data from ongoing longitudinal rodent sampling to link ecological fluctuations with human seroconversion [18]. Conclusion LASV exposure in rural Nigeria is highly variable and likely driven by complex, hyper-local factors. These findings caution against reliance on broad-scale risk mapping for public health planning. Effective control requires shifting toward adaptable, household-focused interventions and, critically, the adoption of granular, One Health surveillance strategies to accurately identify high-transmission sites for clinical research and vaccine deployment. Supporting information Modelled village population sizes. Estimates of the total population size for the nine surveyed villages, utilized to inform sampling frames and demographic quotas. (JPG) Participant flow diagram. Flowchart detailing the systematic enrollment of households and individuals, including exclusions and the final number of participants included in the serological and risk factor analyses. (JPG) Univariable analysis of risk factors for Lassa virus seropositivity. Unadjusted Odds Ratios (OR) and 95% Credible Intervals (CrI) from Bayesian hierarchical models assessing demographic, environmental, occupational, and behavioral predictors of exposure. (DOCX) Posterior summaries for prevalence models. Median estimates and 95% Credible Intervals (CrI) on the probability scale (expressed as percentages) for overall, state-level, and village-level Lassa virus IgG seroprevalence. (DOCX) Posterior summaries for age-seroprevalence GAM parameters. Central estimates and 95% Credible Intervals (CrI) on the logit scale for the village-level intercepts and smooth term standard deviations extracted from the Bayesian Generalized Additive Model. (DOCX) Spatial heterogeneity of risk factors between villages. Posterior summaries of the random effect standard deviations (SD) quantifying the magnitude of between-village variance for the assessed explanatory variables. (DOCX) 8 Mar 2026 -->PNTD-D-26-00136 Local heterogeneity in Lassa fever serology in rural Nigeria: Implications for control strategies and vaccine trial site selection PLOS Neglected Tropical Diseases Dear Dr. Simons, Thank you for submitting your manuscript to PLOS Neglected Tropical Diseases. After careful consideration, we feel that it has merit but does not fully meet PLOS Neglected Tropical Diseases's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript within by May 07 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosntds@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pntd/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: * A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below. * A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. * An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. We look forward to receiving your revised manuscript. Kind regards, David Safronetz, Ph.D. Section Editor PLOS Neglected Tropical Diseases David Safronetz Section Editor PLOS Neglected Tropical Diseases Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-4304-636XX Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-1765-0002 Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 1) Thank you for including an Ethics Statement for your study. Please include: i) A statement that formal consent was obtained (must state whether verbal/written) OR the reason consent was not obtained (e.g. anonymity). NOTE: If child participants, the statement must declare that formal consent was obtained from the parent/guardian.]. 2) Please upload all main figures as separate Figure files in .tif or .eps format. For more information about how to convert and format your figure files please see our guidelines: https://journals.plos.org/plosntds/s/figures 3) We have noticed that you have uploaded Supporting Information files, but you have not included a list of legends. Please add a full list of legends for your Supporting Information files after the references list. 4) Please amend your detailed Financial Disclosure statement. This is published with the article. It must therefore be completed in full sentences and contain the exact wording you wish to be published. 1) State the initials, alongside each funding source, of each author to receive each grant. For example: "This work was supported by the National Institutes of Health (####### to AM; ###### to CJ) and the National Science Foundation (###### to AM)." 2) State what role the funders took in the study. If the funders had no role in your study, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." 3) If any authors received a salary from any of your funders, please state which authors and which funders.. If you did not receive any funding for this study, please simply state: u201cThe authors received no specific funding for this work.u201d Reviewers' Comments: Reviewer's Responses to Questions Key Review Criteria Required for Acceptance? As you describe the new analyses required for acceptance, please consider the following: Methods -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? -Is the study design appropriate to address the stated objectives? -Is the population clearly described and appropriate for the hypothesis being tested? -Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? -Were correct statistical analysis used to support conclusions? -Are there concerns about ethical or regulatory requirements being met? Reviewer #1: The study was designed based on predicted models and estimates of seroprevalence to guide the number of participants needed for statistical power. However, the actual measured rates of seropositivity in individuals were much lower than expected, which made it difficult for the authors to derive any meaningful conclusions from the survey results. Were correct statistical analysis used to support conclusions? If the goal is to develop a model that helps to find which communities are expected to have higher exposure rates to LASV then interpreting the significance of individual predictors is not the right approach. The effect of predictors can be masked by other correlated predictors. Testing different multivariate models using an approach like cross-validation would be more useful as it would help to determine the out-of-sample accuracy. Using significance tests (albeit Bayesian ones) as a basis to decide whether parameters are useful in a predictive model also ignores an advantage of regularizing priors, namely that predictors with low effects or weak evidence will have their coefficients shrunk toward 0 and little impact on the outcome. In this context, it might make more sense to use a full multivariate model as a baseline prediction model (including all the predictors the authors think are relevant) and evaluate which predictors can be removed without losing predictive power. Reviewer #2: The manuscript by Simons and colleagues presents a cross-sectional serosurvey aimed at estimating the seroprevalence of Lassa fever virus (LASV) antibodies in rural Nigerian populations. This study is important for understanding the distribution of LASV in Nigeria, specifically within rural communities across the states of Benue, Ebonyi, and Cross River. Testing a total of 1,874 individuals, the study reports an overall seroprevalence of 3.3%, with substantial heterogeneity observed across both states and neighboring villages. While the findings are valuable, several issues require further clarification, which could strengthen the conclusions of the study. The manuscript does not provide sufficient detail on the sensitivity and specificity of the commercial ELISA kit used for detecting LASV IgG antibodies. Given the potential impact of assay performance on the accuracy of seroprevalence estimates, it is crucial to address whether the assay was validated against samples from Lassa fever survivors or other well-established reference populations. The statement that "the high specificity of the commercial ELISA kit (LASV vs. non-LASV arenaviruses) may yield more conservative estimates than alternative serological assays" is problematic. The authors must provide actual sensitivity and specificity data to substantiate these claims. Without this information, it is difficult to assess whether the assay’s performance is adequate for the conclusions drawn, and whether the observed seroprevalence is reflective of true exposure rather than assay limitations. Another critical issue is the use of dried blood spots (DBS) as a sampling method. The manuscript does not provide adequate detail on the validation of DBS for the detection of LASV IgG antibodies. Specifically, it is unclear whether the sensitivity and specificity of the ELISA assay were evaluated when using DBS samples, and how these may differ from serum samples. DBS is commonly used in field studies, but it is important to confirm that the performance of the assay with DBS is comparable to that with traditional blood collection methods. Given that the assay detected few positive cases, it is essential to determine whether the use of DBS could have contributed to this low detection rate. Reviewer #3: The methods are generally well-described. The primary concern involves the use of dried blood spots (DBS) instead of serum. The authors should detail any modifications to the ELISA protocol in the methods section and provide the supporting validation data. Reviewer #4: 1) The methods and overall study design and objective are clear and well presented. 2) The authors employ are relatively new commercial LASV IgG assay - that while potentially useful, is not well validated in terms of comparison to other assays. The authors should bring out this source of potential variation in light of differences with other studies completed using similar epidemiologic study designs in Nigeria. 3) Why were no attempts made (or at least not mentioned in this manuscript regarding IgM assessment? 3) Sample size and study population descriptions appear adequate and sufficient to support the study objectives. ********** Results -Does the analysis presented match the analysis plan? -Are the results clearly and completely presented? -Are the figures (Tables, Images) of sufficient quality for clarity? Reviewer #1: Why do the authors set "past_rodent_consumption" to missing if the individual reports current consumption of rodents? (file 07_descriptive_table_analysis.R lines 219-220) This seems like it dramatically reduces the number of cases (and therefore the power) for this predictor? It could be argued that, when looking at serology, past consumption is more relevant than current consumption of rodents since antibodies are accumulated over years and decades. The authors do a good job on making the raw data and all analysis code public. However, the paper should provide citations and version numbers for the packages used, especially tidyverse, brms, RStan (used by brms). Many packages are maintained by funded projects and rely on the citation counts to justify their continued funding. In Figure 1, the colours used make it difficult to identify the corresponding village lines and associated ribbon lines. The ribbon lines are hard to distinguish for Benue and Cross River especially. Please clarify or use different colours if possible. For Figure 3, it is unclear what the different shapes and colours mean on each village map. For example, what does a blue triangle represents, or a red triangle? Also, having two circles represent two different parameters such as either “Not significant” or “Seropositive” makes it difficult to interpret. Please clarify. Reviewer #2: The study finds no consistent demographic, environmental, or behavioral risk factors associated with seropositivity, including rodent consumption. However, this conclusion may be premature. The study does not provide a detailed analysis of the variables considered and how they were incorporated into the statistical models. It would be helpful to see a more comprehensive examination of the potential confounders or biases, as the lack of clear associations may be due to insufficient stratification or power. Further exploration of how these variables were defined and handled in the Bayesian hierarchical models would improve the interpretation of the results. The manuscript lacks detailed information about the populations tested, especially considering Nigeria's detailed record-keeping on Lassa fever cases. The authors should provide additional context regarding the prevalence of Lassa fever in the surveyed regions and whether the seroprevalence aligns with expectations for these areas. It would also be beneficial to provide more context on whether the high or low prevalence states were overrepresented in the survey, and whether this could have influenced the findings. Greater transparency regarding the selection of villages and the demographics of the study population would help readers understand the external validity of the results. Reviewer #3: All results are presented clearly and comprehensively. Reviewer #4: 1) Overall the results present match the intended analysis plan and seem to provide adequate information to the reader to draw conclusions in a clear and concise manner. 2) Tables and figures appear appropriate for this type of epidemiologic serosurvey study. ********** Conclusions -Are the conclusions supported by the data presented? -Are the limitations of analysis clearly described? -Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? -Is public health relevance addressed? Reviewer #1: Some of the conclusions the authors draw about the shape of the estimated age seroprevalence curves appear somewhat unjustified. The only curve that appears not to include both positive and negative slopes is the one for Ogamanna. This could be due to an increasing chance of having been exposed as age increases (as the authors suggest but is absent from all other locations) or evidence of a wave of LASV exposures a few decades back. It is unclear why the authors suggest that a new resurgence of LASV in local rodents would lead to an inverted curve with young people more susceptible to exposure. One would suspect that if there is active, ongoing viral circulation within an area that all populations would be equally as susceptible? The authors do elude to the possibility that older individuals may be more “protected” due to historical exposures, however, there was no meaningful association found for age as a correlate of LASV seropositivity based on the data presented. The authors do a good job of highlighting the limitations of the analysis – including acknowledging the lower than expected seropositivity rates which in turn limited the authors’ power for individual-level risk factor analysis. The authors’ data shows that being located within a high-risk state or Local Government Area does not guarantee high local exposure, and may impact the utility of choosing these areas for potential clinical trial sites. The authors highlight the need for active serosurveys and longitudinal monitoring of rodent reservoirs to help site selection, rather than relying on passive surveillance data. Reviewer #2: The paper makes reference to prior serosurveys but provides little in the way of direct comparative data. A more robust discussion of how these findings compare with previous studies would be valuable for placing the results in a broader context. It would be useful to include data from prior surveys that have tested similar populations and used similar methods, especially if they report contrasting findings. This comparison could also help clarify the heterogeneity in seroprevalence between villages and states. Reviewer #3: The conclusions are well-supported by the data, and their public health implications are thoroughly discussed. If the impact of DBS on assay sensitivity and specificity remains unquantified, this uncertainty should be explicitly addressed as a study limitation. Reviewer #4: 1) Overall the conclusions on this article are insightful into the fine-scale variability of LASV exposure in the human population in the study area of Nigeria. 2) In this reviewers opinion - a major limitation that should be more explored or at least acknowledged more fully is the utilization of relatively new diagnostic assay modality for LASV IgG assessment. It would be worthwhile to provide a better comparison of this approach to previous serological tests to provide context for readers who are not likely to be familiar with these technical differences. 3) The authors overstate the "extreme" nature of the variability of seropositivity among the population. This reviewer appreciates that they are trying to draw attention to the fact that zoonotic virus spillover is indeed a stocastic process that lies on a gradient of risk. However - in each household examined typically only one individual was found to be seropositive and ratios of pos/neg individuals while variable were not "extreme". This type of verbiage is unnecessary and is overselling what the data supports. 4) The conclusions are informative about the challenges of placing upcoming LASV vaccine candidate Phase III efficacy trials at study sites. This is perhaps the most important conclusion from this work of relevance to public health. In the introduction the authors state that these findings influence trial "recruitment", but this is not correct. The key conclusion is that "site selection" will be critical to assess what locations may provide sufficient detections of acute LASV exposure and infection. Recruitment is simply the enrollment of the participants based on inclusion and exclusion critieria. Please adjust this text for clarity for the reader. 5) Much more informative and relevant to the current status of LASV force of infection in the communities studies would be to assess the detection of IgM in these communities. The authors should explicitly state why this was not done in the discussion and what that type of longitudinal followup could provide for trial study site selection etc. This is especially important considering that likely most LASV infections are mild to sub-clinical. ********** Editorial and Data Presentation Modifications? Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”. Reviewer #1: In the abstract, under the Methods section, lines 26 to 33 is essentially repeated in the Results section, refer to lines 34 to 40. These sentences belong more to the results section and should be removed from the methods section. Reviewer #2: The abstract contains several redundancies that detract from its clarity and conciseness. It would benefit from rewriting to eliminate repetitive statements and streamline the presentation of key findings. A clearer and more concise abstract would better highlight the manuscript's key contributions and help readers quickly understand the main conclusions. Reviewer #3: (No Response) Reviewer #4: 1) Overall, the authors tend to present their finding of local variation in LASV IgG as something that is somewhat surprising. This reviewer thinks that it would be helpful to moderate that overall tone a bit and put their findings in the context of what is seen with several other VHFs and other zoonotic pathogens. Clearly this is a critically important finding and will inform efforts to conduct rigorous site-selection for upcoming Phase III LASV vaccine candidate clinical trials. Adding some context would be helpful to strengthen the central take home message from this manuscript. 2) Supplementary Table 1: Why are data fields marked as "strong evidence" if the 95% CI include 1.0? Is this a data table presentation issue - or is the description on the methods sections regarding this table inaccurate (lines 192-194). 3) The authors mention several times about the need for "One Health" approaches to the implementation of human vaccine trial designs. The manuscript would be improved if a short description of what the authors mean by that statement could be included for clarity for readers who are not familiar with that subject. ********** Summary and General Comments Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed. Reviewer #1: The goal of this research was to help identify potential sites for Phase III clinical trials to test LASV vaccines and to study potential local drivers of transmission. The authors wanted to assess if current broad-scale risk maps of LASV transmission can serve as good predictors for clinical trial site selection. In this study, a cross-sectional serosurvey was conducted including over 1800 indiviuals across 9 rural villages in Nigeria. These individuals were tested for levels of LASV IgG as a measure of past LASV infection and also participated in a questionnaire that covered various demographic, environmental, behavioural and occupational risk factors. The overall seropositivity rates were much lower than expected and extremely variable, as a result, no meaningful associations with risk factors included in the questionnaire were found. The findings from this work is somewhat useful for those wishing to identify good sites for Phase III clinical trials for LASV vaccines, highlighting the deficiencies of relying on broad-based risk maps in Nigeria and the need for active surveillance not only in humans but in the rodent hosts as well. While insight is provided for vaccine trial site selection, limited control strategies are provided as implied in the title of this manuscript. Local causes of Lassa virus transmission remains poorly understood, although the authors acknowledge that other factors such as density of local rodent populations may be important but were not included in this study. Broad regional risk mapping or generalized risk profiles may not be representative of current transmission dynamics. Reviewer #2: The lack of detailed assay validation, the unexplained use of dried blood spots, and the need for further exploration of the risk factors associated with seropositivity are all significant limitations. Additionally, further information about the population tested and comparison with prior serosurveys would strengthen the manuscript. Reviewer #3: Simons et al. present a Lassa virus serosurvey across three Nigerian states, reporting an unexpectedly low seroprevalence. Although various factors were assessed for their association with Lassa virus exposure, no consistent patterns emerged. Overall, the study design and data analysis adhere to high standards, and the manuscript is well-written. Minor point: Reference 13 is incomplete. Reviewer #4: Overall, this manuscript describes the heterogeneity of accumulated life-time exposure to LASV as measured by IgG antibodies. This is an important finding relating to the eventual implementation of Phase III LASV vaccine candidate Phase III trials. Insights into the drivers of this finding were somewhat limited by poor correlation with specific risk factors, but perhaps not surprising given the overall very high rodent exposures across the study population over long time periods. A major improvement would be to add IgM detection among the study cohort to ascertain the levels of asymptomatic/sub-clinical infections in the study population. ********** PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No Reviewer #4: No Figure resubmission: While revising your submission, we strongly recommend that you use PLOS’s NAAS tool (https://ngplosjournals.pagemajik.ai/artanalysis) to test your figure files. NAAS can convert your figure files to the TIFF file type and meet basic requirements (such as print size, resolution), or provide you with a report on issues that do not meet our requirements and that NAAS cannot fix. --> After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript.--> Reproducibility: To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols --> 21 Apr 2026 Submitted filename: pntd_review_response.docx 10 May 2026 PNTD-D-26-00136R1 Local heterogeneity in Lassa fever serology in rural Nigeria: Implications for vaccine trial site selection PLOS Neglected Tropical Diseases Dear Dr. Simons, Thank you for submitting your manuscript to PLOS Neglected Tropical Diseases. After careful consideration, we feel that it has merit but does not fully meet PLOS Neglected Tropical Diseases's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript within by Jun 09 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosntds@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pntd/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: * A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below. * A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. * An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, David Safronetz, Ph.D. Section Editor PLOS Neglected Tropical Diseases David Safronetz Section Editor PLOS Neglected Tropical Diseases Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-4304-636XX Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-1765-0002 Additional Editor Comments : Please review comments by reviewers 2 and address appropriately. ********** Note: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Reviewers' Comments: Reviewer's Responses to Questions Key Review Criteria Required for Acceptance? As you describe the new analyses required for acceptance, please consider the following: Methods -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? -Is the study design appropriate to address the stated objectives? -Is the population clearly described and appropriate for the hypothesis being tested? -Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? -Were correct statistical analysis used to support conclusions? -Are there concerns about ethical or regulatory requirements being met? Reviewer #2: The methods are appropriate. The use of LASV IgG seropositivity as the primary outcome is a major strength, as it captures the large burden of subclinical infection and therefore provides a much more accurate picture of exposure than case-based data. The selection of a high-specificity nucleoprotein-based ELISA is appropriate. False positives would undermine site selection. The analysis is fundamentally constrained by low seroprevalence, with only 61 seropositive individuals, which substantially limits statistical power. This makes it difficult to detect modest but meaningful associations across the 21 risk factors and increases the likelihood of type II error. This should be discussed in more detail. Reviewer #3: (No Response) ********** Results -Does the analysis presented match the analysis plan? -Are the results clearly and completely presented? -Are the figures (Tables, Images) of sufficient quality for clarity? Reviewer #2: The analysis matches the plan. The results clearly and completely presented. THe Figures and Tables are of good quality. Reviewer #3: (No Response) ********** Conclusions -Are the conclusions supported by the data presented? -Are the limitations of analysis clearly described? -Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? -Is public health relevance addressed? Reviewer #2: The empirical observations are effectively integrated into a broader One Health framework, with implications for vaccine trial design. However, several of its central interpretations extend beyond what the data can firmly support. Reviewer #3: (No Response) ********** Editorial and Data Presentation Modifications? Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”. Reviewer #2: The manuscript is well written and presented. Reviewer #3: (No Response) ********** Summary and General Comments Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed. Reviewer #2: The inclusion of 21 pre-specified risk factors spanning demographic, environmental, behavioural, and occupational domains is appropriate to avoid post hoc inference. Importantly, the lack of consistent associations is an informative result that challenges prevailing assumptions about spillover risk. Similarly, the spatial analysis is methodologically rigorous, distinguishing between broad and fine-scale clustering. The finding that only a small fraction of seropositive households fall within identified hotspots provides useful, if limited, evidence against simple spatial aggregation. Major concerns are as follows: 1. Tthe conclusion that there are no consistent individual-level risk factors is too definitive. A more accurate interpretation is that the study was underpowered to detect such associations under conditions of low prevalence and limited exposure variability. The discussion should be modifued. 2. The near ubiquity of certain exposures, such as rodent presence in households, which further obscures potential effects. This should be discussed. 3. The interpretation that risk is driven primarily by stochastic, localized ecological factors is plausible but not directly demonstrated by the data. The absence of detectable associations with measured human behaviors does not necessarily imply that ecology is the dominant driver; alternative explanations include measurement error in self-reported behaviors, misalignment between current behaviors and past exposure, and the absence of direct ecological measurements such as rodent density or infection prevalence. This conclusion should be modified. 4. The conclusion that transmission is not spatially clustered should be treated with caution, as the ability to detect clustering is limited under low-prevalence conditions, may be sensitive to the choice of spatial scale, and is constrained by the sampling design, which captures only a subset of individuals per household. This conclusion should be modified. 5. The cross-sectional design limits causal inference, as seropositivity reflects past exposure without precise temporal resolution. This complicates interpretation of both risk factors and age-specific patterns, which may reflect a mixture of recent transmission, historical exposure, and antibody waning. Although the authors appropriately avoid formal force-of-infection modeling, they nonetheless draw relatively strong conclusions from age-seroprevalence curves that are not fully identifiable given the available data and should be modified. 6. The reduced sensitivity of dried blood spot sampling likely biases detection toward recent or higher-titer infections and may underrepresent cumulative exposure in older individuals, potentially exaggerating apparent peaks in younger age groups. This should be discussed. Reviewer #3: The authors have addressed my comments and have incorporated them sufficiently into the manuscript. ********** PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] Figure resubmission: -->While revising your submission, we strongly recommend that you use PLOS’s NAAS tool (https://ngplosjournals.pagemajik.ai/artanalysis) to test your figure files. NAAS can convert your figure files to the TIFF file type and meet basic requirements (such as print size, resolution), or provide you with a report on issues that do not meet our requirements and that NAAS cannot fix.-->--> After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript.--> Reproducibility: To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols --> 12 May 2026 Submitted filename: pntd_review_response_R2.docx 14 May 2026 Dear Dr. Simons, We are pleased to inform you that your manuscript 'Local heterogeneity in Lassa fever serology in rural Nigeria: Implications for vaccine trial site selection' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases. Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests. Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated. IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript. Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS. Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases. Best regards, David Safronetz, Ph.D. Section Editor PLOS Neglected Tropical Diseases David Safronetz Section Editor PLOS Neglected Tropical Diseases Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-4304-636XX Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-1765-0002 *********************************************************** p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; line-height: 16.0px; font: 14.0px Arial; color: #323333; -webkit-text-stroke: #323333}span.s1 {font-kerning: none--> Dear Dr. Simons, We are delighted to inform you that your manuscript, "Local heterogeneity in Lassa fever serology in rural Nigeria: Implications for vaccine trial site selection," has been formally accepted for publication in PLOS Neglected Tropical Diseases. We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication. The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly. Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers. For Research Articles, you will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases. Best regards, Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases